Baillie Gifford & Co. Reduces Position in Illumina, Inc. $ILMN

Baillie Gifford & Co. reduced its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 3.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,626,776 shares of the life sciences company’s stock after selling 59,916 shares during the quarter. Baillie Gifford & Co. owned approximately 1.06% of Illumina worth $213,368,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Board of the Pension Protection Fund purchased a new stake in shares of Illumina in the fourth quarter valued at approximately $26,000. Quent Capital LLC purchased a new stake in shares of Illumina in the third quarter valued at approximately $29,000. Quarry LP purchased a new stake in shares of Illumina in the third quarter valued at approximately $32,000. Aster Capital Management DIFC Ltd purchased a new stake in Illumina in the third quarter worth about $33,000. Finally, Flagship Harbor Advisors LLC purchased a new stake in Illumina in the fourth quarter worth about $33,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Analysts highlight Illumina’s strong earnings-surprise history and say the company currently has the characteristics that make another quarterly beat likely — a bullish near-term earnings catalyst that can support the stock ahead of the April 30 report. Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report? Zacks: Will Illumina (ILMN) Beat Estimates Again?
• Neutral Sentiment: Illumina confirmed it will report Q1 2026 results after the close on Thursday, April 30, with a management conference call scheduled — a clear near-term event that could drive volatility depending on revenue/guide vs. expectations. Illumina to Announce First Quarter 2026 Financial Results
• Neutral Sentiment: Market coverage notes recent share-price strength (outperformance since Oct‑2025) but also that Illumina still lags broader market measures on some timeframes — useful context for momentum and relative-performance trades. MarketWatch: Illumina stock rises, still underperforms market
• Neutral Sentiment: A valuation/peer piece compares Illumina to Regeneron as potential value plays in the biomedical/genetics space — useful for investors weighing sector alternatives but not an immediate directional catalyst. REGN or ILMN: Which Is the Better Value Stock Right Now?
• Negative Sentiment: A Seeking Alpha analysis argues that competitive threats (new platforms, pricing pressure) are an ongoing headwind and may already be reflected in the stock — a cautionary take that can temper upside expectations and increase sensitivity to execution. Illumina: Competitive Threats Priced In
• Negative Sentiment: A recent “3 Reasons to Avoid ILMN” article outlines concerns (valuation after the run, execution/risks) that may be driving some profit‑taking and cautious positioning despite recent strong results. 3 Reasons to Avoid ILMN and 1 Stock to Buy Instead

Illumina Stock Performance

NASDAQ ILMN opened at $120.93 on Monday. The stock has a 50-day simple moving average of $123.95 and a two-hundred day simple moving average of $123.65. The firm has a market capitalization of $18.37 billion, a P/E ratio of 22.19, a PEG ratio of 2.32 and a beta of 1.49. Illumina, Inc. has a fifty-two week low of $69.83 and a fifty-two week high of $155.53. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.09. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The firm had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.10 billion. During the same quarter in the previous year, the business earned $0.95 EPS. Illumina’s revenue for the quarter was up 5.0% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. On average, equities analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analyst Ratings Changes

ILMN has been the subject of a number of research reports. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Illumina in a research note on Monday, December 29th. Stifel Nicolaus upped their target price on Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. Piper Sandler lowered their target price on Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a report on Monday, February 9th. Robert W. Baird set a $137.00 target price on Illumina in a report on Friday, February 6th. Finally, Guggenheim upped their target price on Illumina from $144.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Six research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $129.69.

Insider Transactions at Illumina

In other Illumina news, SVP Patricia Leckman sold 2,370 shares of Illumina stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the completion of the sale, the senior vice president directly owned 16,321 shares of the company’s stock, valued at $1,896,173.78. The trade was a 12.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.17% of the stock is owned by corporate insiders.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.